BACKGROUND: CYP17, which encodes cytochrome P450c17a, mediates both steroid 17a-hydroxylase and 17,20-lyase activities, and is essential for the production of glucocorticoids and sex steroids. There is evidence that a common polymorphism in CYP17 (T27C) is associated with estrogen levels, making it a potential marker of disease risk. METHODS: This is the first study to examine the relationship between CYP17 and estradiol (E 2 ) using serum sampled exclusively from the early follicular phase of the menstrual cycle. We assessed the relationship between CYP17 and serum hormone levels, menstrual cycle length, bleed length, and age at menarche in 164 premenopausal women. RESULTS: Among women with body mass index (BMI) #25 kg/m 2 , those with the TC and CC genotypes had 19 and 42% higher E 2 (P for trend 0.007) and 14 and 30% higher dehydroepiandrosterone sulphate respectively (P for trend 0.10) than women with the TT genotype. Androstenedione levels did not differ between genotypes. Among women with BMI >25 kg/m 2 , hormone levels did not differ by genotype. Women with the C allele were also more likely to have menstrual cycle lengths < 27 days [odds ratio (OR) for TC 5 2.36, 95% confidence interval (CI) 5 1.24-4.52; OR for CC 5 5.59, 95% CI 5 1.53-20.43 compared to TT]. CYP17 genotype was not associated with menstrual bleed length or age at menarche. CONCLUSION: The CYP17 T27C polymorphism may be a marker of endocrine function.
Introduction
CYP17, which encodes cytochrome P450c17a, mediates both steroid 17a-hydroxylase and 17,20-lyase activities, and is essential for the production of glucocorticoids and sex steroids ( Figure 1 ). In women, CYP17 is expressed in the adrenals, adipose tissue, ovarian theca cells, and the corpus luteum (Sasano et al., 1989; Hanukoglu, 1992; Puche et al., 2002) . Mutations in CYP17 cause 17-hydroxylase deficiency (17OHD), a rare form of congenital adrenal hyperplasia (Costa-Santos et al., 2004) . Approximately 40 different mutations in CYP17 have been reported to cause 17OHD that is characterized by hypertension, hypokalaemia, and sexual infantilism (Martin et al., 2003; Costa-Santos et al., 2004) . The absence of 17,20-lyase activity in these individuals results in impaired production of gonadal sex steroids and high levels of basal progesterone (which is a substrate of 17a-hydroxylase) (Martin et al., 2003) . These severe phenotypes demonstrate the importance of CYP17 in the synthesis of androgens and estrogens. Carey et al. (1994) first identified a single nucleotide polymorphism (T27C) in the 5' untranslated region (UTR) of CYP17 and hypothesized that the C allele might up-regulate gene expression leading to increased levels of serum hormones, including androstenedione and estradiol (E 2 ). This polymorphism is common; the CC genotype is present in 11 -19% of North American whites and 6 -16% of AfricanAmericans (Sharp et al., 2004) . Several studies support the hypothesis that the CYP17 C allele may be a marker of increased steroidogenesis. It has been associated with increased risk of recurrent spontaneous abortion (Sata et al., 2003) , a condition associated with high androstenedione levels (Li et al., 2002) . It has also been associated with decreased risk of intrauterine growth retardation (Yamada et al., 2004) which is consistent with the observed positive correlation between pregnancy estrogen levels and fetal size (Peck et al., 2003) . Further, the C allele has been associated with increased risk of uterine leiomyomas (Amant et al., 2004) which is consistent with the proliferative effect of estrogen on the endometrium (Deligdisch, 2000) .
The T27C polymorphism could affect estrogen levels through several postulated mechanisms. Carey et al. (1994) suggested that the addition of an Sp-1 type (CCACC box) recognition site may up-regulate gene transcription and increase circulating hormones, but molecular evidence does not support this (Nedelcheva Kristensen et al., 1999) . Other possible mechanisms, including transcriptional elongation or effects on mRNA translation rates, have not been tested experimentally. Alternatively, up-regulation of gene expression may result from another functional site in linkage disequilibrium with T27C. Regardless of the mechanism for up-regulation, this polymorphism may prove to be a significant marker of disease risk if it is associated with estrogen levels in pre-menopausal women.
Few studies have directly assessed whether the T27C polymorphism is associated with hormone levels in pre-menopausal women, and the results have been inconsistent. Feigelson et al. (1998) first reported increased E 2 and progesterone associated with the C allele, but two subsequent studies (Garcia-Closas et al., 2002; Travis et al., 2004) were unable to confirm this finding. These studies did not restrict serum collection to a limited range of cycle days as done by Feigelson et al. In all three studies, hormones were measured predominantly during the late follicular and luteal phases. Because menstrual cycle length, particularly follicular phase length, varies among women, measurement of hormones during the late follicular and luteal phases may be confounded by cycle length. The goal of this study was to examine whether differences in hormone levels by genotype are present in the early follicular phase. Because previous studies have shown differential tissue-specific regulation of CYP17 in the ovary and adipose tissue (Puche et al., 2002) , we also explored whether the effect of CYP17 on hormone levels is modified by body mass index (BMI).
Materials and methods
Study population CYP17 study participants were drawn from a larger study examining the relationship between the repeat size polymorphism in the 5' UTR of the fragile X mental retardation (FMR1) gene and female reproductive ageing. All of the women included in this analysis had FMR1 repeat size #150. Specific details on the population recruitment are reported elsewhere (Sullivan et al., 2005) . Briefly, women were enrolled between June 2000 and January 2004 from the general population and through families with a relative with fragile X syndrome. A total of 507 women aged 18-75 years completed a reproductive history questionnaire and gave buccal and/or blood samples. In the reproductive history questionnaire, women selfreported usual menstrual cycle and bleed length, and age at menarche. Women who were post-menopausal, pregnant, amenhorrhoeic, or who had hysterectomy, bilateral oophorectomy, or a history of radiation or chemotherapy were excluded from this study. Women with unclear cycling status, or who were taking HRT or fertility medications also were excluded. The final study sample consists of 164 women. The analysis of menstrual cycle length and bleed length does not include women using oral contraceptives (n = 53). The study was approved by the Institutional Review Board at Emory University, Atlanta, GA.
Hormone analysis
Blood samples were drawn between day 2 and day 7 of the menstrual cycle. Ninety-three per cent of the samples were collected between day 2 and day 5. After collection, blood was stored on ice, and processing occurred within 3 h. Serum was stored at 2 808C until the hormone assays were carried out. The Laboratory of Behavioural Neuroscience and Neuroimmunology at Emory University performed radioimmunoassays for E 2 , androstenedione (ASD) and dehydroepiandrosterone sulphate (DHEA-S) (Diagnostics Systems Laboratories Inc.). The ASD assay had standards ranging from 0.05 to 10 ng/ml. The DHEA-S assay had standards ranging from 25 to 8000 ng/ml. The E 2 assay had standards ranging from 0.75 -150 pg/ml (DSL 3rd generation E 2 assay). Hormones were assayed in duplicate, and the duplicate values were averaged for our analysis. For our samples, the within-assay coefficient of variation (CV) was 3.2% for ASD, 1.9% for DHEA-S, and 3.8% for E 2 . Samples were run in three batches, and the between-assay CV ranged from 2.6 to 7.5% depending on the hormone measured and the level of the internal control. DHEA-S for one woman could not be obtained because of insufficient serum.
Genotyping analysis DNA was extracted from buffy coats of peripheral blood samples. CYP17 genotyping was performed, as described in detail elsewhere (Carey et al., 1994) . Briefly, a fragment containing the T27C substitution was amplified with the following primers: CYP-1 (forward), 5'-CATTCGCACTCTGGAGTC-3' and CYP-2 (reverse), 5'-AGGC-TCTTGGGGTACTTG-3'. PCR reactions were carried out in 22 ml aliquots containing ,100 ng of DNA, 0.5 ml of each primer, and 10 £ reaction buffer (containing 500 mmol/l Tris, 100 mmol/l KCl, 2 ml MgCl2, 1 IU of Taq polymerase, and 1.25 mmol/l deoxynucleotide triphosphates). An initial denaturation step was run at 948C for 5 min, followed by 30 cycles of amplification with denaturation at 948C for 1 min, annealing at 578C for 1 min, and extension at 728C CYP17 genotype predicts serum hormone levels for 1 min. This was followed by a final extension at 728C for 5 min. The MspA1 restriction enzyme was used to digest the PCR fragments at 378C for 2 h. Fragments were separated by gel electrophoresis and stained with ethidium bromide to identify the base pair substitution.
Approximately 5% of the samples were repeated for quality control of genotyping. The repeat analyses were run blind and the agreement of the repeated samples was 100%.
Statistical analysis
Unadjusted mean values and SE were calculated for the six outcomes of interest: E 2 , DHEA-S, ASD, cycle length, bleed length, and age at menarche. These results were stratified by CYP17 genotype.
Eighteen per cent of the women in our sample were related. To account for the dependency of related women, generalized estimating equations (GEE) (Zeger and Liang, 1986) were used to evaluate the relationship between CYP17 genotype and hormone levels or reproductive characteristics. We compared these results to models including only unrelated women. We coded CYP17 genotype ordinally based on the number of C alleles, and tested the statistical significance of the trend.
Prior to modelling, hormone levels were log-transformed to improve normality. Using GEE models, we estimated the adjusted geometric mean hormone levels and SE. Potential confounders, including age (continuous), BMI (kg/m 2 ; continuous), race (white, African-American, Hispanic, Asian, other), current smoking (yes/no), parity (continuous), current oral contraceptive use (yes/no) and cycle day of blood collection (continuous) were chosen a priori based on our understanding of endocrinology and CYP17 biology. Age and race were included in all models. Other potential confounders were retained if their removal changed the parameter estimate for the association between CYP17 genotype and hormone concentration by .10%.
Because of differences in hormone synthesis between the ovaries and adipose tissue, we evaluated the interaction between BMI and CYP17. BMI was categorized as # 25 or . 25 kg/m 2 , based on the World Health Organization definition of overweight and obesity, and separate models were constructed for each BMI category. We also examined whether there was effect modification by race by including an interaction term between CYP17 genotype and race.
The self-report of reproductive characteristics showed strong digit preference. Therefore, we categorized these outcomes and modelled the probability of menstrual cycle length , 27 days, bleed length ,5 days, and menarche prior to 12 years. These thresholds reflect the lowest 25% of each distribution. Using GEE, we generated odds ratios (OR), representing the odds of being in the lowest 25% for the TC and CC genotype as compared to the reference group, the TT genotype, and 95% confidence intervals (CI). We compared these analyses with results from logistic regression models including only unrelated women.
The analysis of menstrual cycle length and bleed length was limited to women not using hormonal contraceptives. Age (continuous), BMI (kg/m 2 ; continuous), race (white/other), current smoking (yes/no), and parity (continuous) were considered potential confounders. Racial groups of Hispanic, Asian, African-American, and other were combined into a single category because of small numbers. Age and race were included in the final models. Other potential confounders were retained if their removal changed the parameter estimate by . 10%. The analysis of age at menarche only included age and race as confounders. BMI and smoking were not included as covariates since we did not have information on these variables at the time of menarche. All analyses were completed with SAS Version 9 (Carey, NC, USA). Table I shows characteristics of the study population stratified by genotype. The study included 164 pre-menopausal women aged 18-52 years (mean 32). The mean BMI was 26 kg/m 2 . Fifty-three per cent of the women had BMI of # 25 kg/m 2 . The women predominantly identified themselves as white (62.8%) and African-American (29.9%). Fifty-three women were current oral contraceptive users while 111 were not. The oral contraceptive users tended to be younger than the non-users (mean age 28.9 versus 33.6 years), but did not differ by race or BMI. Genotype distribution was 37% TT, 50% TC and 13% CC, and the allele frequencies were in Hardy -Weinberg equilibrium (x2 = 0.351, df = 2, P = 0.82).
Results
Unadjusted analyses showed that the association between CYP17 genotype and hormone level did not differ between oral contraceptive users and non-users, so these results were combined. The unadjusted results in Table II show that women with the C allele had increased estradiol and DHEA-S, and decreased cycle length, bleed length, and age at menarche. Hormone levels in women were correlated: the correlation between E 2 and DHEA-S was 0.23 (P = 0.004); between E 2 and ASD was 0.21 (P = 0.008); and between DHEA-S and ASD was 0.57 (P , 0.0001). Table III shows geometric mean hormone level by CYP17 genotype and BMI adjusted for age, race, current smoking and oral contraceptive use. Among women with BMI # 25, those with the TC and CC genotypes had 19 and 42% higher serum E 2 respectively than women with the TT genotype (P for trend 0.007). Women with the TC and CC genotypes had 14 and 30% higher serum DHEA-S respectively than women with the TT genotype (P for trend 0.10). ASD levels did not differ between genotypes. Among women with BMI . 25 kg/m 2 , hormone levels did not differ by genotype. These results did not change when the analysis was limited to women who were not using oral contraceptives. Further, adjusting for cycle day of serum collection and parity did not alter the findings, and there was no effect modification by race (data not shown).
As shown in Table IV , among women who do not use oral contraceptives, those who have the C allele were more likely have cycle lengths , 27 days controlling for age, race and BMI (OR for TC = 2.36, 95% CI = 1.24 -4.52; OR for CC = 5.59, 95% CI = 1.53 -20.43; P for trend = 0.009). When this threshold was changed to , 28 days, the association was similar (OR for TC = 2.34, 95% CI = 1.18-4.64; OR for CC = 5.46 95% CI = 1.38 -21.56; P for trend = 0.02, data not shown). These results were consistent with the decrease in mean cycle length among women with the C allele shown in the unadjusted results (Table II) . Adjusting for current smoking and parity did not alter the findings. No association was seen between CYP17 genotype and bleed length or age at menarche.
The results of the models in Tables III and IV were similar whether the analysis accounted for the dependency of related individuals, assumed independence between women, or was restricted to unrelated individuals (data not shown).
Discussion
Among pre-menopausal women with a low to moderate BMI, the CYP17 C allele was associated with serum E 2 in a dose-dependent manner providing evidence that E 2 may be up-regulated as a result of this polymorphism. E 2 production is downstream of CYP17 activity. The production of DHEA and ASD occurs upstream and in closer proximity to CYP17 activity (Figure 1) . Therefore, if CYP17 up-regulates E 2 , one may expect increases in DHEA-S (the reservoir for DHEA) and ASD as well. We found a non-significant trend for a dose-dependent increase in DHEA-S, but no significant increase in ASD among women with low to moderate BMI. This is the first study to document the modifying effect of BMI on the relationship between CYP17 and serum hormone levels. Increases in E 2 and DHEA-S associated with the C allele were limited to women with BMI # 25 kg/m 2 . This suggests that the effect of the C allele may be limited to ovarian rather than adipose production of E 2 . There are at least two possible explanations for this. Differential tissuespecific regulation of CYP17 in the ovary and adipose tissue has been suggested by recent molecular investigations (Puche et al., 2002) . Alternatively, the C allele may up-regulate steroid production in all women, but the relative proportion of end-products may vary among those with BMI . 25 kg/m 2 due to differences downstream in steroid biosynthesis. Corbould et al. (2002) found that the ratio of 17b-hydroxysteroid dehydrogenase3 mRNA to CYP19 mRNA in adipose tissue was positively correlated with obesity. This suggests that steroid production in adipose tissue of obese women may be turned towards the production of testosterone rather than estrone and E 2 . This may also explain the result that Hormone levels for women with BMI #25 kg/m 2 .
c Self-reported usual cycle length and bleed length among women not using hormonal contraceptives. E 2 = estradiol; DHEA-S = dehydroepiandrosterone sulphate; ASD = androstenedione. Two-sided test for trend by number of C alleles. BMI = body mass index; E 2 = estradiol; DHEA-S = dehydroepiandrosterone sulphate; ASD = androstenedione; OC = oral contraceptive.
CYP17 genotype predicts serum hormone levels low BMI was associated with higher E 2 levels, which is consistent with some previous studies of pre-menopausal women (Manson et al., 2001; Baghaei et al., 2002; Randolph et al., 2003) . The relationship between CYP17 and E 2 was first documented among young (18 -33 years), nulliparous women with low BMI (mean = 22.8 kg/m 2 , interquartile range 20.1-24.5) (Feigelson et al., 1998) . Despite differences in the age and parity of our populations, the percentage increases in E 2 in our early follicular phase samples (19 and 42% for TC and CC as compared to TT, respectively, among BMI # 25 kg/m 2 ) are similar to those seen on day 11 by Feigelson et al. (11 and 57%) . Two other studies of pre-menopausal women found no relationship between the CYP17 genotype and serum E 2 (Garcia-Closas et al., 2002; Travis et al., 2004) . However, serum was not collected within a limited range of cycle days. Rather, the analysis was stratified by cycle phase (without a biological measure of ovulation) and adjusted by self-reported cycle day. This may have resulted in misclassification and an attenuated effect. Furthermore, neither study assessed the potential effect of BMI.
Five studies of post-menopausal women did not find an association between CYP17 genotype and E 2 (Haiman et al., 2001; Berstein et al., 2002; Dunning et al., 2004; Travis et al., 2004; Tworoger et al., 2004) . The only study to restrict their analysis to postmenopausal women with BMI , 25 found the CC genotype associated with higher urinary estrone and estradiol (Onland-Moret et al., 2005) . Furthermore, both the levels of endogenous estrogens and the mechanisms for estrogen production differ between pre-and post-menopausal women, possibly explaining the discrepant results between studies (Speroff et al., 1999) .
Our analyses of reproductive characteristics provides indirect evidence that the T27C polymorphism regulates endocrine function. Women with the C allele were more likely to have cycle lengths , 27 days. Higher estrogen metabolite levels have been associated with shorter cycles (Windham et al., 2002) and shorter follicular phase length (Harlow et al., 2000) , suggesting a mechanism for this association. Our study participants self-reported menstrual cycle length. Because error in recall is likely distributed evenly across genotypes, error would result in bias toward the null.
Given that our population was drawn from a reproductive study of FMR1 repeat size, it may not reflect characteristics of the general population. However, controlling for FMR1 repeat size in our analyses or limiting our analyses to women with FMR1 repeat , 60 (the more common repeat sizes in the general population) did not alter our findings. This is the first study to examine the relationship between CYP17 and E 2 using serum sampled exclusively from the early follicular phase of the menstrual cycle. E 2 levels vary greatly during the menstrual cycle, and such variation is closely tied to the timing of ovulation, and follicular and luteal phase length. Determining the day of ovulation requires a labour-intensive protocol of collecting biological samples throughout the majority of the menstrual cycle. In the absence of these data, we suggest that a more consistent measure of E 2 levels across women can be obtained during the early follicular phase. Michaud et al. (1999) found that early follicular phase serum E 2 had better reproducibility across cycles than luteal phase E 2 . Although Ahmad et al. (2002) found that E 2 levels from day 9 to day 11 were more consistent, their population was restricted to women with regular cycles. Furthermore, Ahmad et al. (2002) found that early follicular phase serum E 2 had the highest correlation to average E 2 across the entire menstrual cycle. Thus, the measurement of serum in the early follicular phase is the most consistent among women with varying cycle lengths.
Our findings, in concert with the earlier results of Feigelson et al. (1998) , highlight the need to examine the relationship between CYP17 and the entire downstream steroid hormone pathway in a large population-based study of young women. The optimal study design would include assessment of hormone levels early in the follicular phase with highly sensitive and specific assays and would carefully control for BMI and central adiposity. Genes involved in steroid biosynthesis and metabolism may play important roles in disease risk directly through influencing hormone levels and indirectly through altering other reproductive endpoints. Polymorphisms in these genes, such as T27C, may help to determine women at increased risk. Controlling for age (continuous) and race (white versus other).
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